Krystal Biotech, Inc. Their mission is to develop innovative gene therapies that can dramatically improve people's lives. They offer treatments for various conditions such as Dystrophic Epidermolysis Bullosa (B-VEC), TGM1-deficient ARCI (KB105), Cystic Fibrosis (KB407), and Netherton Syndrome (KB104).

In addition to these specific therapies, Krystal Biotech also provides treatments for other dermatological indications. Their gene therapy treatments are designed to offer hope to patients and their families who face chronic skin diseases and aesthetic skin conditions. With their STAR-D platform and a focus on patient advocacy, Krystal Biotech is committed to making a positive impact in the medical community.

For more information about their products and services, visit their website or contact them directly